PL2909340T3 - Diagnostyczna metoda przewidywania reakcji na inhibitor TNF ALFA - Google Patents

Diagnostyczna metoda przewidywania reakcji na inhibitor TNF ALFA

Info

Publication number
PL2909340T3
PL2909340T3 PL13789899T PL13789899T PL2909340T3 PL 2909340 T3 PL2909340 T3 PL 2909340T3 PL 13789899 T PL13789899 T PL 13789899T PL 13789899 T PL13789899 T PL 13789899T PL 2909340 T3 PL2909340 T3 PL 2909340T3
Authority
PL
Poland
Prior art keywords
diagnostic method
tnf alpha
alpha inhibitor
predicting response
predicting
Prior art date
Application number
PL13789899T
Other languages
English (en)
Inventor
László Nagy
Bertalan Meskó
László Steiner
Gábor Zahuczky
Zsolt Holló
Original Assignee
Egyt Gyogyszervegyeszeti Gyar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egyt Gyogyszervegyeszeti Gyar filed Critical Egyt Gyogyszervegyeszeti Gyar
Publication of PL2909340T3 publication Critical patent/PL2909340T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL13789899T 2012-10-19 2013-10-18 Diagnostyczna metoda przewidywania reakcji na inhibitor TNF ALFA PL2909340T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU1200607A HU230680B1 (hu) 2012-10-19 2012-10-19 Diagnosztikai eljárás
PCT/HU2013/000101 WO2014060785A2 (en) 2012-10-19 2013-10-18 DIAGNOSTIC METHOD FOR PREDICTING RESPONSE TO TNFα INHIBITOR
EP13789899.5A EP2909340B1 (en) 2012-10-19 2013-10-18 Diagnostic method for predicting response to tnf alpha inhibitor

Publications (1)

Publication Number Publication Date
PL2909340T3 true PL2909340T3 (pl) 2018-01-31

Family

ID=89990915

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13789899T PL2909340T3 (pl) 2012-10-19 2013-10-18 Diagnostyczna metoda przewidywania reakcji na inhibitor TNF ALFA

Country Status (12)

Country Link
US (1) US20160194709A1 (pl)
EP (1) EP2909340B1 (pl)
JP (1) JP2016502400A (pl)
CA (1) CA2889087C (pl)
DK (1) DK2909340T3 (pl)
EA (1) EA037105B1 (pl)
ES (1) ES2645972T3 (pl)
HU (1) HU230680B1 (pl)
NO (1) NO2909340T3 (pl)
PL (1) PL2909340T3 (pl)
UA (1) UA118658C2 (pl)
WO (1) WO2014060785A2 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016179469A1 (en) * 2015-05-07 2016-11-10 Abbvie Inc. Methods and compositions for diagnosing and treating inflammatory bowel disease
EP3313993A4 (en) 2015-06-29 2019-06-19 Regents of the University of Minnesota ANTI-APOBEC3 ANTIBODIES AND METHOD OF PREPARATION AND USE
GB2547406A (en) * 2015-11-20 2017-08-23 Folkersen Lasse Apparatus and methods of using of biomarkers for predicting TNF-inhibitor response
GB201521357D0 (en) * 2015-12-03 2016-01-20 Univ Liverpool Methods for predicting response to anti-TNF therapy
US20190085405A1 (en) * 2016-03-23 2019-03-21 Regents Of The University Of Minnesota Methods of detecting apobec3 expression and predicting clinical outcomes
US20200399698A1 (en) * 2018-02-19 2020-12-24 Genefron Ltd. Methods of determining response to tnf alpha blockers
JP7496324B2 (ja) 2018-03-16 2024-06-06 サイファー メディシン コーポレイション 抗tnf療法に対する応答性を予測するための方法及びシステム
US20220099686A1 (en) * 2018-11-30 2022-03-31 Cha University Industry-Academic Cooperation Foundation Brain-derived vesicle-specific marker and brain disease diagnostic method using same
US20220073988A1 (en) * 2018-12-07 2022-03-10 Dna Chip Research Inc. Method for predicting efficacy of rheumatoid arthritis therapeutic agent and biomarker used therein
GB2603294A (en) 2019-06-27 2022-08-03 Scipher Medicine Corp Developing classifiers for stratifying patients
KR102429261B1 (ko) * 2020-08-25 2022-08-03 충북대학교 산학협력단 한국인의 tnf 저해제 약물 반응성 예측을 위한 바이오마커
KR102941328B1 (ko) * 2023-02-20 2026-03-20 재단법인 아산사회복지재단 크론병에 대한 항-tnf 치료 반응성을 예측하기 위한 동반진단용 바이오마커 조성물
EP4621071A1 (en) * 2024-03-22 2025-09-24 Fundación Pública Galega Instituto de Investigación Sanitaria de Santiago de Compostela In vitro method for predicting the response of patients suffering from rheumatoid arthritis to a treatment with tumor necrosis factor (tnf) inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000058362A1 (en) * 1999-03-26 2000-10-05 Human Genome Sciences, Inc. Neutrokine-alpha binding proteins and methods based thereon
EP1613350B1 (en) * 2003-04-09 2009-03-18 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
EP1857559A1 (en) * 2006-05-16 2007-11-21 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for predicting responsiveness to TNF alpha blocking agents
AR065910A1 (es) * 2007-04-02 2009-07-08 Genentech Inc Marcadores biologicos pronosticos de la respuesta de la artritis reumatoide a los antagonistas de los linfocitos b
WO2008132176A2 (en) * 2007-04-27 2008-11-06 Universite Catholique De Louvain Method for evaluating the response of an individual to tnf blocking therapy
WO2008150491A2 (en) * 2007-05-31 2008-12-11 Abbott Laboratories BIOMARKERS PREDICTIVE OF THE RESPONSIVENESS TO TNFα INHIBITORS IN AUTOIMMUNE DISORDERS
ES2445892T3 (es) * 2008-08-25 2014-03-05 Janssen Biotech, Inc. Biomarcadores para el tratamiento anti-TNF en colitis ulcerosa y trastornos relacionados
JP2011004743A (ja) * 2009-06-26 2011-01-13 Dna Chip Research Inc 関節リウマチ患者におけるインフリキシマブ薬効の有効性を判別する方法
WO2012061620A1 (en) * 2010-11-04 2012-05-10 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis

Also Published As

Publication number Publication date
DK2909340T3 (da) 2017-11-13
EP2909340A2 (en) 2015-08-26
HUP1200607A2 (en) 2014-04-28
HU230680B1 (hu) 2017-08-28
CA2889087A1 (en) 2014-04-24
UA118658C2 (uk) 2019-02-25
NO2909340T3 (pl) 2017-12-30
EA037105B1 (ru) 2021-02-05
EA201590773A1 (ru) 2015-09-30
JP2016502400A (ja) 2016-01-28
US20160194709A1 (en) 2016-07-07
CA2889087C (en) 2021-11-16
ES2645972T3 (es) 2017-12-11
EP2909340B1 (en) 2017-08-02
WO2014060785A2 (en) 2014-04-24
WO2014060785A3 (en) 2014-06-12

Similar Documents

Publication Publication Date Title
PL2909340T3 (pl) Diagnostyczna metoda przewidywania reakcji na inhibitor TNF ALFA
EP2904115A4 (en) BIOMARKERS AND METHODS FOR PREDICTING RESPONSE TO INHIBITORS AND USES THEREOF
SG10201707548RA (en) Method for predicting sensitivity to egfr inhibitor
IL229114B (en) Methods for predicting clinical response of a cancer patient to certain treatments using cereblon as a predictor
DK3415915T3 (da) Fremgangsmåde til at forudsige respons til PARP-inhibitorer
PL2825719T3 (pl) Sposób obsługi odwiertów
IL219844A0 (en) Detection of tenting
GB201007159D0 (en) Method for evaluating anglogenic potential
EP2855745A4 (en) METHODS RELATING TO ADALIMUM AB
SG11201401774VA (en) Immunobinders directed against tnf
SG10201602147YA (en) Methods And Compositions For Predicting Response To Eribulin
PL2485026T3 (pl) System monitorowania stanu technicznego struktury
SG11201401212TA (en) Probe unit
EP2637017A4 (en) METHOD FOR MEASURING FILLING CAPACITY
EP2685257A4 (en) METHOD OF ANALYSIS
EP2775844A4 (en) BIOMARKER FOR THE RESPONSE TO NAE INHIBITORS
EP2867766A4 (en) BACKGROUND PROVIDED BY APPLICATION FOR PREDICTING POTENTIAL ACTION
EP2720873A4 (en) METHOD AND ASSEMBLY FOR DETECTING FLUIDS
GB201212069D0 (en) Predicting resistance to disease
GB201218341D0 (en) Diagnostic method
AP2013007084A0 (en) Diagnostic method
GB2503401B (en) Method and system for determining HRV and RRV and use to identify potential condition onset
GB201100223D0 (en) Diagnostic method
PL2888228T3 (pl) Inhibitory oddziaływania CD40-TRAF6
GB201502129D0 (en) System for visual expression of acoustic information